ICARES Medicus (ROCO:6612) ROCE %: 6.04% (As of Dec. 2025)

What is ICARES Medicus ROCE %?

ICARES Medicus ROCO:6612 +1.12% 84 ROCE % is 6.04% as of Dec. 2025. GuruFocus rates ROCO:6612 with a GF Score™ of 84/100 and a GF Value™ of NT$188.98 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ICARES Medicus's annualized ROCE % for the quarter that ended in Dec. 2025 was 6.04%.

ICARES Medicus (ROCO:6612) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ICARES Medicus ROCE % Related Terms

ICARES Medicus ROCE % Historical Data

* Premium members only.

The historical data trend for ICARES Medicus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ICARES Medicus ROCE % Chart

ICARES Medicus Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

9.06

15.96

8.81

8.66

3.85

ICARES Medicus Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															9.05	9.44	-1.22	1.20	6.04

84GF Score

ICARES Medicus Inc ROCO:6612

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ICARES Medicus ROCE % Calculation

ICARES Medicus's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	91.915	/	( ( (3008.195 - 573.803)	+	(3179.996 - 833.459) )	/ 2 )
	=	91.915	/	( (2434.392	+	2346.537)	/ 2 )
	=	91.915	/	2390.4645
	=	3.85 %

ICARES Medicus's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	139.596	/	( ( (3140.767 - 861.634)	+	(3179.996 - 833.459) )	/ 2 )
	=	139.596	/	( ( 2279.133	+	2346.537 )	/ 2 )
	=	139.596	/	2312.835
	=	6.04 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 6.04% mean?

ICARES Medicus (ROCO:6612) has a ROCE % of 6.04% as of Dec. 2025.

Is ICARES Medicus' ROCE % too high?

ICARES Medicus' current ROCE % is 6.04%. The Medical Devices & Instruments industry median ROCE % is 2.20. ICARES Medicus' value of 6.04% is 174.5% above this industry median. Overall, ICARES Medicus has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does ICARES Medicus' ROCE % compare to ISRG and BDX?

ICARES Medicus' ROCE % of 6.04% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. ICARES Medicus' value of 6.04% is 174.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current ROCE % of 6.04% is 174.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current ROCE % is 6.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ICARES Medicus stock overvalued right now?

Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$188.98, compared to a current price of NT$72.40 — trading 61.7% below its estimated fair value. The current ROCE % is 6.04% and 174.5% above the Medical Devices & Instruments industry median of 2.20. ICARES Medicus' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current ROCE % is 6.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICARES Medicus (ROCO:6612) Overvalued in 2026?

Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued. The current stock price of NT$72.40 is trading 61.7% below its estimated GF Value™ of NT$188.98. GuruFocus considers ICARES Medicus to be Possible Value Trap.

Key valuation signals for ROCO:6612:

ROCE %: 6.04%
GF Value™: NT$188.98 vs. price of NT$72.40 (61.7% below fair value)
GF Score™: 84/100 with 7 warning signs
Industry Position: 174.5% above the Medical Devices & Instruments median

No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICARES Medicus Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TPE:1752 TPE:1783 TPE:1786 TPE:4737 ROCO:1565 ROCO:6527 ROCO:4111 ROCO:4116 ROCO:6730 ROCO:5312 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address Section 2, Shengyi Road, No. 16, 4th Floor, Hsinchu County, Zhubei, TWN, 30261

Website https://www.icaresmedicus.com

ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.

84GF Score

Get the complete analysis for ROCO:6612

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$72.40

Price

NT$188.98

GF Value

View ROCO:6612 Analysis

See ROCE % data for all stocks →